ALLIANCE PHARMACEUTICALS LIMITED
Get an alert when ALLIANCE PHARMACEUTICALS LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2026-08-08 (in 3mo)
Last made up 2025-07-25
Watchouts
None on the register
Cash
£16M
+103.9% vs 2023
Net assets
£43M
+7.6% vs 2023
Employees
204
+3% vs 2023
Profit before tax
£5M
+110.9% vs 2023
Net assets
2-year trend · vs Consumer Staples median
Accounts
2-year trend · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Turnover | £125,207,000 | £128,940,000 | |
| Operating profit | -£18,425,000 | £22,194,000 | |
| Profit before tax | -£43,431,000 | £4,730,000 | |
| Net profit | -£37,636,000 | £3,227,000 | |
| Cash | £7,755,000 | £15,811,000 | |
| Total assets less current liabilities | £321,019,000 | £301,457,000 | |
| Net assets | £39,849,000 | £42,869,000 | |
| Equity | £39,849,000 | £42,869,000 | |
| Average employees | 198 | 204 | |
| Wages | £13,043,000 | £17,487,000 |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating margin | -14.7% | 17.2% | |
| Net margin | -30.1% | 2.5% | |
| Return on capital employed | -5.7% | 7.4% | |
| Gearing (liabilities / total assets) | 89.2% | 87.8% | |
| Current ratio | 1.92x | 1.83x | |
| Interest cover | -0.74x | 0.93x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 101
- Reporting scope
- Standalone (parent only)
- Auditor
- Deloitte LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The Directors, in concluding that the going concern basis is appropriate, have received from Alliance Pharma Limited (formerly Alliance Pharma plc) a letter of support confirming Alliance Pharma Limited will continue to provide the financial resources require to fund the Company's operations for the foreseeable future and at least 12 months from the date of signing of the Financial Statements. After making enquiries, the Directors have a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. Based on their assessment of the Company's financial position, they continue to adopt the going concern basis in preparing the Financial Statements.”
Group structure
- ALLIANCE PHARMACEUTICALS LIMITED · parent
- Advanced Bio-Technologies Inc. 100%
- Alliance Pharma Inc. 100%
- Alliance Pharma S.r.l. 100%
- Alliance Pharmaceuticals (Thailand) Co., Limited 100%
- Alliance Pharmaceuticals (Philippines) Corporation 100%
- Alliance CHC (India) Private Limited 90%
- Opus Healthcare Limited 100%
- Alliance Pharma (Ireland) Limited 100%
- Alliance Consumer Health Limited 100%
- Alliance Generics Limited 100%
- Alliance Health Limited 100%
- Alliance Healthcare Limited 100%
- Caraderm Limited 100%
- Dermapharm Limited 100%
- Macuvision Europe Limited 100%
- Maelor Laboratories Limited 100%
- Opus Group Holdings Limited 100%
Significant events
- “On 10 January 2025, Alliance Pharma Limited (formerly Alliance Pharma plc) announced the recommended cash offer by DBAY Advisors Ltd for the entire issued, and to-be-issued share capital of Alliance Pharma Limited (the ultimate parent of Alliance Pharmaceuticals Limited). The acquisition was completed on 14 May 2025, and Alliance Pharma Limited ceased trading on AIM as of 15 May 2025.”
- “Other than the change in ultimate parent company disclosed in note 22, there were no material events subsequent to 31 December 2024 and up until the authorisation of the financial statements for issue.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
3 active · 20 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| CHRYSANTHOU, Chrysanthos Theoclis | Secretary | 2017-09-01 | — | — |
| LEESE, Jonathan Mark | Director | 2026-04-30 | May 1980 | British |
| SEDGWICK, Nicholas John | Director | 2024-05-13 | Aug 1972 | British |
Show 20 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| BELLHOUSE, Robin Christian | Secretary | 2016-12-31 | 2017-09-01 |
| DAWSON, Stella Anne | Secretary | 1996-09-16 | 2002-01-10 |
| RANSON, Paul | Secretary | 2007-05-16 | 2007-08-03 |
| ROBINSON, Sarah Nicole | Secretary | 2011-03-21 | 2016-12-31 |
| SCOTT, Madeleine Elizabeth | Secretary | 2002-01-10 | 2007-05-16 |
| WRIGHT, Richard David | Secretary | 2007-08-03 | 2011-03-21 |
| SWIFT INCORPORATIONS LIMITED | Corporate Nominee Secretary | 1996-09-16 | 1996-09-16 |
| BOOLEY, Anthony Richard | Director | 2000-04-14 | 2016-06-30 |
| BUTTERFIELD, Peter Jonathan | Director | 2010-02-22 | 2024-06-30 |
| DAWSON, John | Director | 1996-09-16 | 2018-04-30 |
| DAWSON, Stella Anne | Director | 2002-01-10 | 2007-05-16 |
| DUGGAN, Alexander James Hanbury | Director | 2018-06-01 | 2025-04-23 |
| FRANKLIN, Andrew Timothy | Director | 2015-09-28 | 2026-04-30 |
| HEPER, Jeyan | Director | 2023-02-01 | 2024-08-31 |
| KIDNER, Stephen Martin | Director | 2018-06-01 | 2022-09-27 |
| RANSON, Paul | Director | 2003-09-01 | 2014-12-31 |
| SCOTT, Madeleine Elizabeth | Director | 2003-09-01 | 2007-05-16 |
| TOMLINSON, Mark John | Director | 2008-09-30 | 2009-07-17 |
| TREVILLION, Richard Ian | Director | 2003-03-01 | 2003-10-14 |
| WRIGHT, Richard David | Director | 2007-08-03 | 2015-05-29 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Alliance Pharma Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2016-04-06 | Active |
Filing timeline
Last 20 of 204 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-04-30 | TM01 | officers | Termination director company with name termination date | |
| 2026-04-30 | AP01 | officers | Appoint person director company with name date | |
| 2025-08-08 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2025-07-17 | MR01 | mortgage | Mortgage create with deed with charge number charge creation date | |
| 2025-07-17 | MR01 | mortgage | Mortgage create with deed with charge number charge creation date | |
| 2025-06-30 | AA | accounts | Accounts with accounts type full | |
| 2025-06-19 | PSC05 | persons-with-significant-control | Change to a person with significant control | |
| 2025-05-28 | MR04 | mortgage | Mortgage satisfy charge full | |
| 2025-05-28 | MR04 | mortgage | Mortgage satisfy charge full | |
| 2025-05-28 | MR04 | mortgage | Mortgage satisfy charge full | |
| 2025-05-28 | MR04 | mortgage | Mortgage satisfy charge full | |
| 2025-05-28 | MR04 | mortgage | Mortgage satisfy charge full | |
| 2025-05-28 | MR04 | mortgage | Mortgage satisfy charge full | |
| 2025-05-28 | MR04 | mortgage | Mortgage satisfy charge full | |
| 2025-05-28 | MR04 | mortgage | Mortgage satisfy charge full | |
| 2025-05-28 | MR04 | mortgage | Mortgage satisfy charge full | |
| 2025-04-24 | TM01 | officers | Termination director company with name termination date | |
| 2025-04-22 | MR04 | mortgage | Mortgage satisfy charge full | |
| 2025-04-22 | MR04 | mortgage | Mortgage satisfy charge full | |
| 2024-12-17 | AA | accounts | Accounts with accounts type full |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 16
- Capital events
- 0
- Officers appointed
- 1
- Officers resigned
- 1
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
-
Turnover
+3%
£125,207,000 £128,940,000
-
Cash
+103.9%
£7,755,000 £15,811,000
-
Net assets
+7.6%
£39,849,000 £42,869,000
-
Employees
+3%
198 204
-
Operating profit
+220.5%
-£18,425,000 £22,194,000
-
Profit before tax
+110.9%
-£43,431,000 £4,730,000
-
Wages
+34.1%
£13,043,000 £17,487,000
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers